Skip to main content
icon for Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ?
Finance·TMO

Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ?

icon for Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ?
Finance·TMO

Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ?

juil. 23

juil. 23

Supérieure à 4 % 40%

2%-4% 33%

0 %-2 % 10.9%

<-2% <1%

Polymarket

$22,711 Vol.

Supérieure à 4 % 40%

2%-4% 33%

0 %-2 % 10.9%

<-2% <1%

Polymarket

$22,711 Vol.

<-2%

$647 Vol.

1%

-2%-0%

$3,417 Vol.

<1%

0 %-2 %

$6,069 Vol.

8%

2%-4%

$4,846 Vol.

33%

Supérieure à 4 %

$7,733 Vol.

55%

This market will resolve according to Thermo Fisher's organic revenue growth (year-over-year) for the upcoming second fiscal quarter, as reported in its official company earnings materials. The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket. If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket. If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket. If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.**Thermo Fisher's Q2 2026 organic revenue growth faces pressure from ongoing U.S. academic research funding reductions and sluggish life-sciences tools demand, following Q1's 1% organic result.** Management raised full-year 2026 guidance to a 3.5% midpoint after Q1, citing pharma and biopharma investments as offsets, yet analysts highlight limited end-market inflection and conservative consensus revenue estimates near $12 billion (roughly 8% reported growth). Recent reports note academic and government client weakness persisting into 2026, contributing to the market-implied emphasis on sub-2% outcomes ahead of the July 23 earnings release. Trader positioning reflects uncertainty around whether quarterly organic performance will align with the annual path or reflect continued softness in core segments.

This market will resolve according to Thermo Fisher's organic revenue growth (year-over-year) for the upcoming second fiscal quarter, as reported in its official company earnings materials.

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.

If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volume
$22,711
Date de fin
23 juil. 2026
Marché ouvert
Jul 8, 2026, 7:08 PM ET

Resolver

0x69c47De9D...
This market will resolve according to Thermo Fisher's organic revenue growth (year-over-year) for the upcoming second fiscal quarter, as reported in its official company earnings materials. The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket. If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket. If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket. If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
This market will resolve according to Thermo Fisher's organic revenue growth (year-over-year) for the upcoming second fiscal quarter, as reported in its official company earnings materials. The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket. If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket. If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket. If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.**Thermo Fisher's Q2 2026 organic revenue growth faces pressure from ongoing U.S. academic research funding reductions and sluggish life-sciences tools demand, following Q1's 1% organic result.** Management raised full-year 2026 guidance to a 3.5% midpoint after Q1, citing pharma and biopharma investments as offsets, yet analysts highlight limited end-market inflection and conservative consensus revenue estimates near $12 billion (roughly 8% reported growth). Recent reports note academic and government client weakness persisting into 2026, contributing to the market-implied emphasis on sub-2% outcomes ahead of the July 23 earnings release. Trader positioning reflects uncertainty around whether quarterly organic performance will align with the annual path or reflect continued softness in core segments.

This market will resolve according to Thermo Fisher's organic revenue growth (year-over-year) for the upcoming second fiscal quarter, as reported in its official company earnings materials.

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.

If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volume
$22,711
Date de fin
23 juil. 2026
Marché ouvert
Jul 8, 2026, 7:08 PM ET

Resolver

0x69c47De9D...
This market will resolve according to Thermo Fisher's organic revenue growth (year-over-year) for the upcoming second fiscal quarter, as reported in its official company earnings materials. The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket. If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket. If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket. If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Connexes

icon for Coca-Cola (KO) croissance organique du chiffre d'affaires au T2 (non-GAAP) de 5% à 6,5% ?

Coca-Cola (KO) croissance organique du chiffre d'affaires au T2 (non-GAAP) de 5% à 6,5% ?

37%
Oui
icon for Croissance organique des ventes d'Amphenol (APH) au deuxième trimestre de 28% à 32% ?

Croissance organique des ventes d'Amphenol (APH) au deuxième trimestre de 28% à 32% ?

41%
Oui
icon for Meta (META) croissance des impressions publicitaires au T2 sur l'ensemble de la Famille d'applications de 16% à 19% ?

Meta (META) croissance des impressions publicitaires au T2 sur l'ensemble de la Famille d'applications de 16% à 19% ?

38%
Oui

Méfiez-vous des liens externes.

Questions fréquentes

« Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ? » est un marché de prédiction sur Polymarket avec 5 résultats possibles où les traders achètent et vendent des parts selon ce qu'ils pensent qu'il se passera. Le résultat en tête actuel est « Supérieure à 4 % » à 56%, suivi de « 2%-4% » à 33%. Les prix reflètent des probabilités en temps réel de la communauté. Par exemple, une part cotée à 56¢ implique que le marché attribue collectivement une probabilité de 56% à ce résultat. Ces cotes changent en permanence. Les parts du résultat correct sont échangeables contre $1 chacune lors de la résolution du marché.

À ce jour, « Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ? » a généré $22.7K en volume total de trading depuis le lancement du marché le Jul 8, 2026. Ce niveau d'activité reflète un fort engagement de la communauté Polymarket et garantit que les cotes actuelles sont alimentées par un large bassin de participants. Vous pouvez suivre les mouvements de prix en direct et trader sur n'importe quel résultat directement sur cette page.

Pour trader sur « Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ? », parcourez les 5 résultats disponibles sur cette page. Chaque résultat affiche un prix actuel représentant la probabilité implicite du marché. Pour prendre position, sélectionnez le résultat que vous estimez le plus probable, choisissez « Oui » pour trader en sa faveur ou « Non » pour trader contre, entrez votre montant et cliquez sur « Trader ». Si votre résultat choisi est correct lors de la résolution, vos parts « Oui » rapportent $1 chacune. S'il est incorrect, elles rapportent $0. Vous pouvez également vendre vos parts avant la résolution.

Le favori actuel pour « Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ? » est « Supérieure à 4 % » à 56%, ce qui signifie que le marché attribue une probabilité de 56% à ce résultat. Le résultat le plus proche ensuite est « 2%-4% » à 33%. Ces cotes sont mises à jour en temps réel à mesure que les traders achètent et vendent des parts. Revenez fréquemment ou ajoutez cette page à vos favoris.

Les règles de résolution de « Croissance organique du chiffre d'affaires de Thermo Fisher (TMO) Q2 (non conforme aux PCGR) ? » définissent exactement ce qui doit se produire pour que chaque résultat soit déclaré gagnant, y compris les sources de données officielles utilisées pour déterminer le résultat. Vous pouvez consulter les critères de résolution complets dans la section « Règles » sur cette page au-dessus des commentaires. Nous recommandons de lire attentivement les règles avant de trader, car elles précisent les conditions exactes, les cas particuliers et les sources.